High-Risk Non-ST Elevation Acute Coronary Syndrome Outcomes in Patients Treated with Unfractionated Heparin Monitored Using Anti-Xa Concentrations versus Activated Partial Thromboplastin Time

Abstract

Background

While the activated partial thromboplastin time (aPTT) is the most widely used assay to monitor unfractionated heparin (UFH), providing a general measure of the extent of anticoagulation, it does not reliably correlate with the blood concentration of heparin or its antithrombotic effect. While cost and availability have limited the widespread use of UFH in hospitals, monitoring UFH with heparin levels has been shown to reduce both the number of monitoring tests and the time to a therapeutic range.

Objectives

To compare outcomes in patients with non-ST elevation acute coronary syndrome (ACS) treated with weight-based UFH monitored with anti-Xa concentrations versus aPTT.

Methods

A retrospective chart review was completed in patients admitted with high-risk ACS and compared to the UFH arm of the SYNERGY trial. The primary outcome included the clinical endpoint of all-cause death or non-fatal myocardial infarction until time of hospital discharge. Safety endpoints evaluated included incidence of stroke and major bleeding.

Results

The primary endpoint occurred in 6.3% of patients in the study cohort compared to 6.5% of patients in the heparin arm of the SYNERGY trial at 48 hours (P = .006). Bleeding was reduced in the study cohort with a significant decrease in GUSTO severe bleeding (P = .007). Additionally the study cohort had significantly fewer patients with an absolute drop in hemoglobin or hematocrit. Thrombolysis in Myocardial Infarction (TIMI) major and minor bleeding, rate of transfusion, and platelet counts were similar between groups.

Conclusions

Outcomes for high-risk ACS patients receiving heparin monitored by anti-Xa concentrations are noninferior to heparin monitored by aPTT.

Keywords

acute coronary syndrome heparin non-ST elevation myocardial infarction

Get full access to this article

View all access options for this article.

References

Harrington

Becker

Cannon

. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th ed). Chest. 2012; 141:e120S-e801S.

Anderson

Adams

Antman

. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50:652–726.

Cohen

Adams

Parry

. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS Trial. Circulation. 1994;89:81–88.

The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–830.

Théroux

Ouimet

McCans

. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–1111.

The SYNERGY Trial Investigators. Enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy (SYNERGY). JAMA. 2004;292:45–54.

Baker

Adelman

Smith

Osborn

. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med. 1997;157:2475–2479.

Hsia

Kleiman

Aguirre

. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. J Am Coll Cardiol. 1992;20:31–35.

Becker

Cannon

Tracy

. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction. Am Heart J. 1996;131:421–433.

10.

Lee

Wali

Menon

. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis. 2002;14:91–101.

11.

Montalescot

Cohen

Salette

. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J. 2008;29:462–471.

12.

Yin

Giudice

Wessler

Inhibition of activated factor X-induced platelet aggregation: the role of heparin and the plasma inhibitor to activated factor X. J Lab Clin Med. 1973;82:390–398.

13.

Anand

Yusuf

Pogue

. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation. 2003;107:2884–2888.

14.

Montalescot

Collet

Tanguy

. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004;110:392–398.

15.

Rosborough

. Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with activated partial thromboplastin time. Pharmacotherapy. 1999;19:760–766.

16.

Kandrotas

Gal

Douglas

Groce

. Rapid determination of maintenance heparin infusion rates with the use of non-steady-state heparin concentrations. Ann Pharmacother. 1993;27:1429–1433.

17.

Gilchrist

Berkowitz

Thompson

. Heparin dosing and outcome in acute coronary syndromes: the GUSTO IIb experience. Am Heart J. 2002;144:73–80.

18.

Turpie

AGG

Robinson

Doyle

. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989;320:352–357.

19.

Bovill

Terrin

Stump

. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI), phase II trial. Ann Intern Med. 1991;115:256–265.

20.

Groce

Gal

Douglas

Steuterman

. Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time. Clin Pharm. 1987;6:216–222.

21.

Francis

Groce

. Challenges in variation and responsiveness of unfractionated heparin. Pharmacotherapy. 2004;24:108S–19S.

22.

The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329: 673–682.

23.

Eikelboom

Mehta

Anand

Changchun

Fox

KAA

Yusuf

Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–782.

24.

Manoukian

Feit

Mehran

. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007;49:1362–1368.

25.

Peterson

Mahaffey

Hasselblad

. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non–ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89–96.